Federal award (PURCHASE ORDER, fiscal year 2022)
Recipient: GENEIMMUNE BIOTECHNOLOGY CORP
Awarding agency: Department of Health and Human Services / National Institutes of Health
Funding agency: Department of Health and Human Services / National Institutes of Health
Period of performance: 2021-09-05 to 2023-04-06
Current total value of award: $151620
Description: FOR COVID-19:  FOR SITE-DIRECTED MUTAGENESIS, GENE SYNTHESIS, AND PLASMID PREP